Home » Topics » Analysis and data insight

Analysis and data insight
RSS

Public financing of biotechnology companies: Follow-on offerings in November 2019

December 6, 2019

Follow-ons completed by biopharma companies in November 2019.

Other financings of public biotechnology companies in November 2019

December 6, 2019

Private placements and other private financings of public biopharma companies in November 2019.

Public financing of biotechnology companies: Completed and pending IPOs in November 2019

December 6, 2019

Completed and pending initial public offerings by biopharma companies in November 2019.

Biopharma companies continue their strong momentum in November

December 3, 2019

By Peter Winter

After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.

asia-india-flag

Indian pharma sector needs to learn from its competitors: report

December 3, 2019

NEW DELHI, India – While India is still an attractive prospect for investment in biotechnology, the country needs to learn from the successful examples of other countries, including its Asian biotech competitors, according to a new report.

In India, government steps up efforts to develop more TB testing and treatment

December 3, 2019

HYDERABAD – India, home to a quarter of the global tuberculosis (TB) cases, plans to enhance its capacity to fight TB drug resistance and bolster susceptibility testing under a new initiative launched by the Geneva-based nonprofit Foundation for Innovative New Diagnostics (FIND).

stock prices up

IPO class of 2019

Biopharma stocks up 26% on average since debut with Karuna as top performer

December 2, 2019

With a 349% increase in stock price since its June debut on U.S. markets, Boston-based Karuna Therapeutics Inc. secures the title of best IPO performer so far in 2019. The stock skyrocketed in November following positive top-line phase II data of Karxt in acute psychosis in patients with schizophrenia, providing a potential read-through to larger indications such as Alzheimer’s disease and pain.

A quick look back at top stories

Blockbuster deals capture attention heading into the Thanksgiving holiday

November 27, 2019

A quick look back at top stories.

Money raised by biopharma: 2019 vs. 2018

November 27, 2019

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.

Biopharma money raised: Jan. 1-Nov. 26, 2019

November 27, 2019

Year-to-date money raised in public, private and other financings of biopharma companies.

Popular Stories

Bioworld MedTech’s Oncology Extra
BioWorld MedTech
Keeping you up to date on recent developments in oncology.
Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity
BioWorld
LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines...
FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system
BioWorld MedTech
The U.S. FDA has cleared Cochlear Ltd.’s newest cochlear implant, the Osia 2 system, an active implantable bone conduction hearing system. Unlike Cochlear’s...
Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms
BioWorld
Commissioner of the FDA for five years starting in 1984, Frank Young relished his position “at the vortex of controversy” as he sought to deal with the AIDS...
Biopharma companies continue their strong momentum in November
BioWorld
After being in the doldrums for the majority of the year, public biopharmaceutical companies, it appears, have turned the corner and are now on a major upswing.

cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.